NOVALEAD PHARMA

NovaLead is a drug discovery research company focused on discovering new indications for generic drugs. Enabled by proprietary technology platform, NovaLead's drug repositioning approach is targeted at finding new biological targets for generic drugs, thereby discovering new indication possibilities. This approach is distinctly differentiated from conventional line extension strategies. NovaLead's business development and outsourced research services are managed by its wholly owned subsidiary - ... Novalead Pharma Inc., USA. NovaLead's discovery pipeline has an addressable market estimated at over US$ 10 billion p.a. The lead candidate in the pipeline is Galnobax®, which is a topical gel for the treatment of hard to heal Diabetic Foot Ulcer (DFU). The recently concluded global Phase – I / II clinical trial has demonstrated that Galnobax® has successfully met both primary and secondary endpoints for safety and efficacy. Given the limitations of existing therapies for DFU, Galnobax® is looked at as a ray of hope by millions of DFU patients worldwide. Entire discovery research of NovaLead is done in-house and entire biological validation is outsourced to service providers with specific expertise around the world. The commercial model of NovaLead is to outlicense / partner its discoveries after first human proof of concept. Headquartered in Pune - India, NovaLead is funded by top tier venture investors from India and Europe.More